Preparing healthcare companies for success
in the value-based economy

2Q 2018 Access Meter Report
NOW AVAILABLE 

more info >

Solutions

Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.

more >

Insights

Real Endpoints is a thought leader within the pharmaceutical industry. We actively publish and lead panels and are frequently quoted in the press.

more >

Our Solutions

Value-Based Dealmaker

Design and orchestrate value-based deals

RxScorecardTM

Guide strategic and development decisions with customized, interactive value framework

Access Meter

Defining payer challenges for emerging drugs with a validated database

Hub ExcellenceTM

Maximize the impact of patient services programs via benchmarking and needs analysis

Reimbursement iQTM

Enhance impact of customer-facing representatives using 360˚analysis

Customer Gateway

Develop customized program to foster goodwill with customers

Communications
and Training

Address customer pain points with targeted materials; strengthen confidence and knowledge of reps via customized training

Advisory and
Market Research

Generate strategic recommendations — conduct qualitative and quantitative research

News and Events

Real Endpoints Appoints Jeff Berkowitz, CEO and Director

by Real Endpoints LLC

Real Endpoints (RE), a leader in the development and implementation of proprietary tools to strengthen pharmaceutical market access for an evolving healthcare landscape, announced today that Jeff Berkowitz, a 20-year veteran of the pharmaceutical, drug distribution, pharmacy and payer industries, has joined the company as CEO and member of the board of directors. Jeff is one of the rare executives whose.....

September 13, 2018

read full press release >

The 2018 FH Global Summit

Speaker: Roger Longman

Real Endpoints LLC

The FH Global Summit is the only conference dedicated to solving global challenges in the care and treatment of familial hypercholesterolemia (FH) through a multi-stakeholder and interdisciplinary approach. An invitation-only event, the summit features a stellar lineup of speakers and panelists who are experts in FH, genomics, precision medicine, alongside leading healthcare practitioners, individuals with FH and industry.

October 1, 2018 -
October 2, 2018

Marina del Rey, CA

event >

AMCP Nexus

Attendee: Real Endpoints team

The Academy of Managed Care Pharmacy (AMCP) is the nation’s leading professional association dedicated to increasing patient access to affordable medicines, improving health outcomes and ensuring the wise use of health care dollars. Through evidence- and value-based strategies and practices, the Academy’s 8,000 pharmacists, physicians, nurses and other practitioners manage medication therapies for the 270 million Americans served by health plans, pharmacy benefit management firms, emerging care models and government.

October 22, 2018 -
October 25, 2018

Orlando, FL

event >

Must Sky-High Prices ‘Come on Down’ Before the Price Is Right?

by Richard Mark Kirkner

The first gene therapy to treat an inherited disease is out of the gate, but with a very high price tag. Many more gene therapies are on their way. How can they be priced to hit the sweet spot of affordability, access, and innovation?

July 25, 2018

Managed Care

read full article >

Recent Insights

view archive >

July 2, 2018

Defining access potential – Before it’s too late

Confirmation bias: when innovators believe in a drug, find the evidence to support its value, and dismiss or ignore the facts challenging their preferred story. Industry and its investors need a clear, objective lens through which they can burn away confirmation bias and see the likely access barriers their drugs will face once approved

Read full insight article >

June 18, 2018

Depression Rising (Again): Turning the Corner in Psychiatry’s Most Burdensome Disorder

For all of the millions who suffer from depression, the biological underpinnings of clinical depression are still not fully understood. With several high profile approval decisions and possible launches on the horizon, the stage is thus set for an emerging commercial case characterized by a new wave of effective anti-depressants, an increasingly influential assortment of payers and practitioners with generic but often ineffectual pharmacotherapy options at their disposal, and of course patients with an unabating level of need and strikingly high placebo response-rates. How will it play out?

read full insight presentation >
Just a quick note of appreciation for your responsiveness throughout the Market Access training process.  Your follow-up on a range of issues was always immediate and the resolution was definitive.  That type of effort and support doesn’t go unnoticed by me.

National Business Director

Top 5 Pharma

We have never seen a diagnostic like this before – it gets right to the heart of the problem.

Senior Director

Specialty Access Solutions, Top 5 Pharma

The insights you provided via Hub Excellence were the most insightful and actionable market research I have ever received.

Director of Operations

Reimbursement and Patient Support Services, Top 20 Pharma

RxScorecard provides a comprehensive, multi-pronged rubric assisting us in decision-making as we begin to move from a volume to value drug evaluation methodology.

Chronis H. Manolis, RPh

Vice President, Pharmacy UPMC Health Plan

We at GSK believe that it’s critical for the pharmaceutical industry to produce drugs that deliver value for patients, providers and payers. We have found RxScorecard to be an insightful framework for assessing and comparing the value of drugs, both marketed and developmental assets. The perspective it provides supports improved customer-focused development and commercialization, and we and our customers can benefit from its use.

Jack Bailey

President , GlaxoSmithKline U.S.